Symbols / NKTR $75.00 +3.86%
NKTR Chart
About
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.10B |
| Enterprise Value | 1.97B | Income | -164.08M | Sales | 55.23M |
| Book/sh | 4.41 | Cash/sh | 8.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -5.87 | PEG | — |
| P/S | 37.99 | P/B | 17.01 | P/C | — |
| EV/EBITDA | -15.22 | EV/Sales | 35.75 | Quick Ratio | 4.62 |
| Current Ratio | 4.97 | Debt/Eq | 165.76 | LT Debt/Eq | — |
| EPS (ttm) | -9.73 | EPS next Y | -12.78 | EPS Growth | — |
| Revenue Growth | -25.30% | Earnings | 2026-05-07 | ROA | -27.98% |
| ROE | -217.94% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -87.54% | Profit Margin | -297.07% | Shs Outstand | 27.98M |
| Shs Float | 26.95M | Short Float | 12.10% | Short Ratio | 2.12 |
| Short Interest | — | 52W High | 77.00 | 52W Low | 6.45 |
| Beta | 1.23 | Avg Volume | 1.12M | Volume | 638.91K |
| Target Price | $136.43 | Recom | Strong_buy | Prev Close | $72.21 |
| Price | $75.00 | Change | 3.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$136.43
Mean price target
2. Current target
$75.00
Latest analyst target
3. DCF / Fair value
$-69.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$75.00
Low
$105.00
High
$165.00
Mean
$136.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | init | TD Cowen | — → Buy | — |
| 2026-03-16 | main | Citigroup | Buy → Buy | $123 |
| 2026-02-23 | reit | B. Riley Securities | Buy → Buy | $150 |
| 2026-02-10 | main | HC Wainwright & Co. | Buy → Buy | $165 |
| 2026-02-10 | main | BTIG | Buy → Buy | $151 |
| 2026-01-29 | reit | BTIG | Buy → Buy | $118 |
| 2025-12-16 | main | HC Wainwright & Co. | Buy → Buy | $135 |
| 2025-12-16 | main | BTIG | Buy → Buy | $118 |
| 2025-11-26 | init | Citigroup | — → Buy | $102 |
| 2025-11-26 | main | Jefferies | Buy → Buy | $121 |
| 2025-09-23 | main | B. Riley Securities | Buy → Buy | $105 |
| 2025-09-19 | reit | BTIG | Buy → Buy | $100 |
| 2025-07-08 | main | B. Riley Securities | Buy → Buy | $85 |
| 2025-06-24 | main | HC Wainwright & Co. | Buy → Buy | $120 |
| 2025-04-11 | up | Jefferies | Hold → Buy | $2 |
| 2025-03-14 | up | Oppenheimer | Perform → Outperform | $6 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-08 | init | B. Riley Securities | — → Buy | $4 |
- Should Mixed Q4 Results and REZOLVE-AA Lawsuits Reshape Nektar Therapeutics’ (NKTR) Rezpegaldesleukin-Focused Strategy? - simplywall.st ue, 17 Mar 2026 16
- Nektar Therapeutics (NKTR) Receives New 'Buy' Rating from TD Cowen | NKTR Stock News - GuruFocus ue, 17 Mar 2026 15
- SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire ue, 17 Mar 2026 12
- Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at TD Cowen - MarketBeat ue, 17 Mar 2026 12
- Nektar Therapeutics stock initiated with buy rating at TD Cowen - Investing.com ue, 17 Mar 2026 10
- Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High? - Yahoo Finance Mon, 16 Mar 2026 13
- Nektar raises $460M ahead of Phase 3 atopic dermatitis trials - Stock Titan hu, 12 Mar 2026 20
- Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Nektar Therapeutics (NKTR) and Eos Energy Enterprises, Inc. (EOSE) - marketscreener.com ue, 17 Mar 2026 18
- NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill Fri, 13 Mar 2026 07
- Wall Street experts project a potential 77.28% increase for Nektar (NKTR): Is such a surge in the stock truly achievable? - Bitget Mon, 16 Mar 2026 15
- NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in N - GuruFocus ue, 17 Mar 2026 15
- Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 12 Mar 2026 21
- Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $123.00 at Citigroup - MarketBeat Mon, 16 Mar 2026 16
- A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals - simplywall.st Sun, 15 Mar 2026 03
- Nektar Therapeutics (NKTR) Analyst Rating Update: Citigroup Rais - GuruFocus Mon, 16 Mar 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 180 | 13140.0 | — | Sale at price 73.00 per share. | ZALEVSKY JONATHAN | Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 423 | 30879.0 | — | Sale at price 73.00 per share. | ROBIN HOWARD W | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 3867 | 137936.0 | — | Sale at price 35.67 per share. | ZALEVSKY JONATHAN | Officer | — | 2026-01-20 00:00:00 | D |
| 3 | 21667 | — | — | Stock Award(Grant) at price 0.00 per share. | ROBIN HOWARD W | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 4 | 6250 | — | — | Stock Award(Grant) at price 0.00 per share. | ZALEVSKY JONATHAN | Officer | — | 2025-12-22 00:00:00 | D |
| 5 | 630 | 34196.0 | — | Sale at price 54.28 per share. | WILSON MARK ANDREW | Officer | — | 2025-11-25 00:00:00 | D |
| 6 | 1157 | 62802.0 | — | Sale at price 54.28 per share. | ZALEVSKY JONATHAN | Officer | — | 2025-11-25 00:00:00 | D |
| 7 | 2207 | 119796.0 | — | Sale at price 54.28 per share. | ROBIN HOWARD W | Chief Executive Officer | — | 2025-11-25 00:00:00 | D |
| 8 | 7110 | — | — | Stock Award(Grant) at price 0.00 per share. | ROBIN HOWARD W | Chief Executive Officer | — | 2025-11-21 00:00:00 | D |
| 9 | 2666 | — | — | Stock Award(Grant) at price 0.00 per share. | ZALEVSKY JONATHAN | Officer | — | 2025-11-21 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -8.28K | 49.56K | -93.00K | -21.53M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.21 |
| NormalizedEBITDA | -118.95M | -111.42M | -114.65M | -220.54M |
| TotalUnusualItems | -9.33M | 24.72M | -128.46M | -102.50M |
| TotalUnusualItemsExcludingGoodwill | -9.33M | 24.72M | -128.46M | -102.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -164.08M | -118.96M | -276.06M | -368.20M |
| ReconciledDepreciation | 1.03M | 4.39M | 7.82M | 13.03M |
| ReconciledCostOfRevenue | 0.00 | 30.69M | 33.77M | 21.64M |
| EBITDA | -128.28M | -86.70M | -243.11M | -323.04M |
| EBIT | -129.30M | -91.09M | -250.92M | -336.07M |
| NetInterestIncome | -15.75M | -13.61M | -6.33M | -22.13M |
| InterestExpense | 26.18M | 28.11M | 25.33M | 28.91M |
| InterestIncome | 10.44M | 14.50M | 19.01M | 6.78M |
| NormalizedIncome | -154.75M | -143.63M | -147.69M | -287.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -164.08M | -118.96M | -276.06M | -368.20M |
| TotalExpenses | 186.00M | 228.34M | 225.35M | 332.29M |
| TotalOperatingIncomeAsReported | -140.10M | -105.20M | -263.68M | -376.17M |
| DilutedAverageShares | 16.87M | 13.71M | 12.67M | 12.48M |
| BasicAverageShares | 16.87M | 13.71M | 12.67M | 12.48M |
| DilutedEPS | -9.73 | -8.68 | -21.75 | -29.55 |
| BasicEPS | -9.73 | -8.68 | -21.75 | -29.55 |
| DilutedNIAvailtoComStockholders | -164.08M | -118.96M | -276.06M | -368.20M |
| NetIncomeCommonStockholders | -164.08M | -118.96M | -276.06M | -368.20M |
| NetIncome | -164.08M | -118.96M | -276.06M | -368.20M |
| NetIncomeIncludingNoncontrollingInterests | -164.08M | -118.96M | -276.06M | -368.20M |
| NetIncomeContinuousOperations | -164.08M | -118.96M | -276.06M | -368.20M |
| EarningsFromEquityInterestNetOfTax | -8.73M | 0.00 | ||
| TaxProvision | -138.00K | -239.00K | -200.00K | 3.21M |
| PretaxIncome | -155.49M | -119.20M | -276.26M | -364.98M |
| OtherIncomeExpense | -8.97M | 24.33M | -134.71M | -102.62M |
| OtherNonOperatingIncomeExpenses | 361.00K | -390.00K | -6.25M | -116.00K |
| SpecialIncomeCharges | -9.33M | 24.72M | -128.46M | -135.93M |
| GainOnSaleOfPPE | 0.00 | -1.30M | 3.33M | |
| GainOnSaleOfBusiness | 0.00 | 40.39M | 0.00 | |
| OtherSpecialCharges | 10.90M | |||
| WriteOff | 0.00 | |||
| ImpairmentOfCapitalAssets | 4.44M | 8.33M | 111.83M | 65.76M |
| RestructuringAndMergernAcquisition | 4.89M | 7.34M | 15.33M | 73.50M |
| GainOnSaleOfSecurity | 33.43M | -8.02M | ||
| NetNonOperatingInterestIncomeExpense | -15.75M | -13.61M | -6.33M | -22.13M |
| InterestExpenseNonOperating | 26.18M | 28.11M | 25.33M | 28.91M |
| InterestIncomeNonOperating | 10.44M | 14.50M | 19.01M | 6.78M |
| OperatingIncome | -130.77M | -129.92M | -135.22M | -240.24M |
| OperatingExpense | 186.00M | 197.66M | 191.58M | 310.66M |
| ResearchAndDevelopment | 117.33M | 120.91M | 114.16M | 218.32M |
| SellingGeneralAndAdministration | 68.67M | 76.75M | 77.42M | 92.33M |
| GeneralAndAdministrativeExpense | 68.67M | 76.75M | 77.42M | 92.33M |
| OtherGandA | 68.67M | 76.75M | 77.42M | 92.33M |
| GrossProfit | 55.23M | 67.74M | 56.35M | 70.42M |
| CostOfRevenue | 0.00 | 30.69M | 33.77M | 21.64M |
| TotalRevenue | 55.23M | 98.43M | 90.12M | 92.06M |
| OperatingRevenue | 55.23M | 98.43M | 90.12M | 92.06M |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 552.33K | 0.00 | ||
| OrdinarySharesNumber | 19.65M | 12.39M | 12.76M | 12.57M |
| ShareIssued | 19.65M | 12.94M | 12.76M | 12.57M |
| TotalDebt | 85.75M | 102.56M | 117.78M | 131.50M |
| TangibleBookValue | 89.83M | 60.74M | 130.99M | 290.14M |
| InvestedCapital | 89.83M | 60.74M | 130.99M | 366.64M |
| WorkingCapital | 212.73M | 199.89M | 279.43M | 477.76M |
| NetTangibleAssets | 89.83M | 60.74M | 130.99M | 290.14M |
| CapitalLeaseObligations | 85.75M | 102.56M | 117.78M | 131.50M |
| CommonStockEquity | 89.83M | 60.74M | 130.99M | 366.64M |
| TotalCapitalization | 89.83M | 60.74M | 130.99M | 366.64M |
| TotalEquityGrossMinorityInterest | 89.83M | 60.74M | 130.99M | 366.64M |
| StockholdersEquity | 89.83M | 60.74M | 130.99M | 366.64M |
| GainsLossesNotAffectingRetainedEarnings | 17.00K | 61.00K | 80.00K | -6.91M |
| OtherEquityAdjustments | 17.00K | 61.00K | 80.00K | -6.91M |
| TreasuryStock | 0.00 | 3.00M | 0.00 | |
| RetainedEarnings | -3.76B | -3.60B | -3.48B | -3.20B |
| AdditionalPaidInCapital | 3.85B | 3.66B | 3.61B | 3.57B |
| CapitalStock | 2.00K | 1.00K | 19.00K | 19.00K |
| CommonStock | 2.00K | 1.00K | 19.00K | 19.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 190.57M | 243.11M | 267.05M | 343.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 137.04M | 181.71M | 215.78M | 275.76M |
| OtherNonCurrentLiabilities | 71.78M | 99.02M | 117.26M | 162.93M |
| DerivativeProductLiabilities | 0.00 | 27.73M | ||
| LongTermDebtAndCapitalLeaseObligation | 65.26M | 82.70M | 98.52M | 112.83M |
| LongTermCapitalLeaseObligation | 65.26M | 82.70M | 98.52M | 112.83M |
| CurrentLiabilities | 53.54M | 61.40M | 51.27M | 68.20M |
| CurrentDebtAndCapitalLeaseObligation | 20.50M | 19.87M | 19.26M | 18.67M |
| CurrentCapitalLeaseObligation | 20.50M | 19.87M | 19.26M | 18.67M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.94M | 2.83M | 5.55M | 9.58M |
| PayablesAndAccruedExpenses | 30.10M | 38.70M | 26.46M | 39.95M |
| CurrentAccruedExpenses | 19.33M | 27.14M | 16.61M | 26.98M |
| Payables | 10.77M | 11.56M | 9.85M | 12.98M |
| AccountsPayable | 10.77M | 11.56M | 9.85M | 12.98M |
| TotalAssets | 280.41M | 303.85M | 398.03M | 710.60M |
| TotalNonCurrentAssets | 14.14M | 42.56M | 67.33M | 164.63M |
| OtherNonCurrentAssets | 5.65M | 4.65M | 4.64M | 2.25M |
| InvestmentsAndAdvances | 3.49M | 26.09M | 25.82M | 0.00 |
| OtherInvestments | 13.87M | 25.82M | ||
| InvestmentinFinancialAssets | 0.00 | 13.87M | ||
| AvailableForSaleSecurities | 13.87M | |||
| LongTermEquityInvestment | 3.49M | 12.22M | 0.00 | |
| InvestmentsInOtherVenturesUnderEquityMethod | 3.49M | 12.22M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 76.50M | 76.50M | |
| Goodwill | 0.00 | 76.50M | 76.50M | |
| NetPPE | 5.00M | 11.82M | 36.86M | 85.89M |
| AccumulatedDepreciation | -15.91M | -86.90M | -124.73M | -148.04M |
| GrossPPE | 5.00M | 11.82M | 123.76M | 210.62M |
| ConstructionInProgress | 245.00K | 739.00K | 2.53M | 7.16M |
| OtherProperties | 5.00M | 11.82M | 56.86M | 102.73M |
| MachineryFurnitureEquipment | 14.64M | 22.98M | 30.47M | 38.92M |
| Properties | 3.88M | 43.18M | 74.89M | 97.39M |
| CurrentAssets | 266.27M | 261.29M | 330.70M | 545.97M |
| OtherCurrentAssets | 15.81M | 23.33M | ||
| PrepaidAssets | 18.73M | 4.46M | 8.73M | 13.38M |
| Inventory | 0.00 | 16.10M | 19.20M | 15.80M |
| FinishedGoods | 0.00 | 1.36M | 5.88M | 3.29M |
| WorkInProcess | 0.00 | 12.88M | 10.75M | 9.34M |
| RawMaterials | 0.00 | 1.86M | 2.58M | 3.17M |
| Receivables | 1.78M | 1.61M | 2.25M | 8.40M |
| OtherReceivables | 1.78M | 1.61M | 1.05M | 2.42M |
| AccountsReceivable | 0.00 | 1.21M | 5.98M | 22.49M |
| CashCashEquivalentsAndShortTermInvestments | 245.75M | 255.23M | 303.62M | 504.98M |
| OtherShortTermInvestments | 230.64M | 210.97M | 268.34M | 416.75M |
| CashAndCashEquivalents | 15.12M | 44.25M | 35.28M | 88.23M |
| CashEquivalents | 23.97M | |||
| CashFinancial | 1.25M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -208.68M | -177.18M | -193.47M | -309.68M |
| RepurchaseOfCapitalStock | 0.00 | -3.00M | 0.00 | |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 180.85M | 0.00 | ||
| CapitalExpenditure | -171.00K | -1.47M | -865.00K | -5.68M |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| IncomeTaxPaidSupplementalData | 76.00K | 2.66M | 272.00K | 325.00K |
| EndCashPosition | 15.12M | 44.25M | 35.28M | 88.23M |
| BeginningCashPosition | 44.25M | 35.28M | 88.23M | 25.22M |
| EffectOfExchangeRateChanges | 6.00K | -4.00K | 62.00K | -327.00K |
| ChangesInCash | -29.14M | 8.98M | -53.01M | 63.34M |
| FinancingCashFlow | 180.57M | 42.12M | 30.00K | 1.51M |
| CashFlowFromContinuingFinancingActivities | 180.57M | 42.12M | 30.00K | 1.51M |
| NetOtherFinancingCharges | -1.15M | 15.00M | 750.00K | 3.00M |
| ProceedsFromStockOptionExercised | 866.00K | 30.12M | 30.00K | 758.00K |
| NetCommonStockIssuance | 180.85M | -3.00M | 0.00 | |
| CommonStockPayments | 0.00 | -3.00M | 0.00 | |
| CommonStockIssuance | 180.85M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| InvestingCashFlow | -1.20M | 142.57M | 139.56M | 365.83M |
| CashFlowFromContinuingInvestingActivities | -1.20M | 142.57M | 139.56M | 365.83M |
| NetInvestmentPurchaseAndSale | -329.00K | 78.65M | 139.18M | 358.31M |
| SaleOfInvestment | 284.68M | 340.36M | 650.88M | 826.23M |
| PurchaseOfInvestment | -285.01M | -261.71M | -511.70M | -467.91M |
| NetBusinessPurchaseAndSale | -697.00K | 65.39M | 0.00 | |
| SaleOfBusiness | 65.39M | 0.00 | ||
| NetPPEPurchaseAndSale | -171.00K | -1.47M | 380.00K | 7.52M |
| SaleOfPPE | 0.00 | 1.25M | 13.20M | 0.00 |
| PurchaseOfPPE | -171.00K | -1.47M | -865.00K | -5.68M |
| OperatingCashFlow | -208.51M | -175.71M | -192.61M | -304.01M |
| CashFlowFromContinuingOperatingActivities | -208.51M | -175.71M | -192.61M | -304.01M |
| ChangeInWorkingCapital | -37.02M | -6.24M | -19.94M | 492.00K |
| ChangeInOtherWorkingCapital | -15.16M | -12.90M | -8.85M | -2.68M |
| ChangeInOtherCurrentAssets | -15.45M | -4.19M | 3.58M | 6.91M |
| ChangeInPayablesAndAccruedExpense | -6.41M | 13.40M | -20.15M | -16.84M |
| ChangeInAccruedExpense | -5.79M | 10.73M | -17.26M | -19.95M |
| ChangeInPayable | -625.00K | 2.67M | -2.88M | 3.10M |
| ChangeInAccountPayable | -625.00K | 2.67M | -2.88M | 3.10M |
| ChangeInInventory | 0.00 | 497.00K | 699.00K | -3.40M |
| ChangeInReceivables | 0.00 | -3.04M | 4.78M | 16.51M |
| ChangesInAccountReceivables | 0.00 | -3.04M | 4.78M | 16.51M |
| OtherNonCashItems | -28.75M | -36.16M | -43.59M | -35.93M |
| StockBasedCompensation | 12.65M | 21.61M | 33.39M | 57.32M |
| ProvisionandWriteOffofAssets | 0.00 | 949.00K | 2.40M | 0.00 |
| AssetImpairmentCharge | 4.44M | 8.33M | 111.83M | 65.76M |
| AmortizationOfSecurities | -5.51M | -9.24M | -14.86M | -2.44M |
| DeferredTax | -140.00K | 2.71M | -102.00K | |
| DeferredIncomeTax | -140.00K | 2.71M | -102.00K | |
| DepreciationAmortizationDepletion | 1.03M | 4.39M | 7.82M | 13.03M |
| DepreciationAndAmortization | 1.03M | 4.39M | 7.82M | 13.03M |
| OperatingGainsLosses | 8.73M | -40.39M | 6.40M | -36.75M |
| EarningsLossesFromEquityInvestments | 8.73M | 0.00 | ||
| GainLossOnInvestmentSecurities | -33.43M | 8.02M | ||
| NetForeignCurrencyExchangeGainLoss | 0.00 | 5.10M | 0.00 | 0.00 |
| GainLossOnSaleOfPPE | 0.00 | 1.30M | -3.33M | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | -40.39M | 0.00 | |
| NetIncomeFromContinuingOperations | -164.08M | -118.96M | -276.06M | -368.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NKTR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|